Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE approves rituximab cancer treatment

  • Comment

Patients with follicular non-Hodgkin’s lymphoma are set to benefit from a treatment recommended by the National Institute for Health and Clinical Excellence.

According to NICE, rituximab could prove to be a “valuable” treatment option for hundreds of patients by delaying the growth and spread of follicular non-Hodgkin’s lymphoma.
 
Its draft guidance states that the drug can be used as a first-line maintenance treatment for people with follicular non-Hodgkin’s lymphoma who have responded to first-line induction therapy with rituximab in combination with chemotherapy.
 
NICE said that analysis showed that treating patients with rituximab maintenance after induction therapy can prevent the spread and growth of the cancer by between three and four years.
 
At present, doctors wait for the cancer to grow again following successful induction therapy, before giving patients further treatment.
 
The manufacturer’s economic modelling also convinced the committee that first-line rituximab maintenance treatment could be a cost-effective use of NHS resources, compared with current clinical practice.
 
Professor Peter Littlejohns, clinical and public health director at NICE, said: “Using rituximab as a maintenance treatment after initial chemotherapy for follicular non-Hodgkin’s lymphoma could be a valuable treatment option for hundreds of patients because no such maintenance treatment has so far been available at this stage of the disease.”
  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs